Results 1 - 10 of 29 : 1 2 3 Next
This Just In: Upgrades and Downgrades
BWS hops off the fence and back onto Sigma Designs.
5 Stocks Approaching Greatness
Investors can find great investments by looking beyond the glare of top-rated stars.
The drugmaker's Copaxone for multiple sclerosis fails to show a benefit at double strength.
FDA Sets a Higher Standard for Merck
Improved cholesterol levels aren't a good enough goal for these drugs.
A Partnership of Habitual Dealmakers
Takeda and Alnylam join forces.
The pharmaceutical cancels a troubled clinical trial.
A Fool peers in through Wall Street's out door.
Will they pull out of the descent or nose-dive into the dirt?
Drugmaker Isis must complete cancer tests before submitting its marketing application.
Glaxo buys into Regulus' microRNA research.
Legal Information © 1995 - 2008 The Motley Fool. All rights reserved.
Market Data provided by 
Terms & Conditions
RSS Headlines
Fool UK